Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 48 of the 49 references it cites were found in a registry or an index; 2 of the 53 sources its claims cite were checked for support.

Recommendations for the management of tyrosinaemia type 1

Open access
de Laet, Corinne, Dionisi-Vici, Carlo, Leonard, James V, McKiernan, Patrick, Mitchell, Grant, Monti, Lidia, de Baulny, Hélène Ogier, Pintos-Morell, Guillem, Spiekerkötter, Ute · 2013 · Orphanet Journal of Rare Diseases

Abstract

The management of tyrosinaemia type 1 (HT1, fumarylacetoacetase deficiency) has been revolutionised by the introduction of nitisinone but dietary treatment remains essential and the management is not easy. In this review detailed recommendations for the management are made based on expert opinion, published case reports and investigational studies as the evidence base is limited and there are no prospective controlled studies. The added value of this paper is that it summarises in detail current clinical knowledge about HT1 and makes recommendations for the management.

Overview

CoChat Summary

## TL;DR

This paper provides expert-opinion recommendations for managing tyrosinaemia type 1, emphasizing rapid nitisinone initiation plus lifelong dietary treatment and close monitoring. It is not based on prospective controlled studies, and the authors explicitly frame the advice as recommendations rather than formal guidelines.

## Key findings

  • Nitisinone has “revolutionised” management, and the recommended immediate dose is 1 mg/kg/day once daily; for acute severe liver failure, 2 mg/kg/day for 48 hours is recommended.
  • Response is usually rapid: coagulation improves within 48 hours, all patients should respond within a week, and succinylacetone in blood and urine should no longer be detectable after the first 24 hours.
  • Long-term risk remains important even on treatment, especially hepatocellular carcinoma (HCC); the paper recommends hepatic imaging at least every 6 months, with MRI/CT every year if the liver is uniform, or every 3–6 months if nodules are present.
  • Dietary management targets plasma tyrosine at 200–400 μmol/l up to about age 12, with some centres allowing up to 500 μmol/l; the paper notes that the safety of allowing higher levels later is not known.

## Methods

  • The paper is an expert consensus review developed by an ad hoc working group of clinicians from Europe and Canada with extensive HT1 experience.
  • The authors state that the literature was reviewed, but evidence was insufficient for formal guidelines; the recommendations were drafted, revised in a workshop, circulated, and iterated until agreement.
  • The recommendations are grounded in published case reports, investigational studies, expert opinion, and unpublished data, with the authors explicitly noting that there were no prospective controlled studies.

## Limitations

  • Stated in the paper: the evidence base is limited, there are no prospective controlled studies, and the output is therefore recommendations rather than formal guidelines.
  • Stated in the paper: several management targets are uncertain, including the optimal plasma nitisinone concentration, the target plasma tyrosine/phenylalanine levels, and the safety of higher tyrosine levels after age 12.
  • Evident from the text: this is an expert consensus/review, so its recommendations depend heavily on specialist opinion and indirect evidence rather than comparative trials.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1186/1750-1172-8-8

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Tyrosine degradation pathway: HT1 is caused by a defect in the fumarylacetoacetase. Succinylacetone is a potent inhibitor of 5-aminolaevulinate dehydratase. Nitisinone inhibits 4-hydydroxyphenylpyruvate dioxygenase reducing flux through the pathway.
Figure 1 Tyrosine degradation pathway: HT1 is caused by a defect in the fumarylacetoacetase. Succinylacetone is a potent inhibitor of 5-aminolaevulinate dehydratase. Nitisinone inhibits 4-hydydroxyphenylpyruvate dioxygenase reducing flux through the pathway.CC BY · PubMed Central
Figure 2 Outline flow diagram of the management of tyrosinaemia type 1. This figure must be used in conjunction with the accompanying text.
Figure 2 Outline flow diagram of the management of tyrosinaemia type 1. This figure must be used in conjunction with the accompanying text.CC BY · PubMed Central

Verification

Claims the paper makes

2 Valid · 25 Not valid · 36 Not checked · 21 Own results and interpretations

27 more claims

Create a free account to see all 84 claims and to verify the 2 references still open.

See all claims — free account
  • It may state two separate claims as one. 35
  • Probably not a substantial claim. 33
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 49 references

Research works printed but not linked: 1

  1. Larochelle J, Alvarez F, Bussières JF, Chevalier I, Dallaire L, Dubois J, Faucher F, Fenyves D, Goodyer P, Grenier A, Holme E, Laframboise R, Lambert M, Lindstedt S, Maranda B, Melançon S, Merouani A, Mitchell J, Parizeault G, Pelletier L, Phan V, Rinaldo P, Scott CR, Scriver C, Mitchell GA: Effect of nitisinone (NTBC) treatment on the clinical course of hepatorenal tyrosinemia in Québec. Mol Genet Metab. 2012, Epub ahead of print

Cited by

See all 227

Metadata

Authors
de Laet, C., Dionisi-Vici, C., Leonard, J. V., McKiernan, P., Mitchell, G., Monti, L., de Baulny, H. O., Pintos-Morell, G., & Spiekerkötter, U.
Affiliations
  • University College London (GB)
  • Birmingham Children's Hospital (GB)
  • Centre Hospitalier Universitaire Sainte-Justine (CA)
  • Bambino Gesù Children's Hospital (IT)
Corresponding author
Leonard, James V
Venue
Orphanet Journal of Rare Diseases
Published
2013-01-11
Volume
8
Issue
1
Pages
8-8
ISSN
1750-1172 (ISSN-L)
OpenAlex
W2097721154
Cited by
227
References
49
Citations by year
2026: 3 · 2025: 14 · 2024: 18 · 2023: 12 · 2022: 14 · 2021: 25 · 2020: 17 · 2019: 22 · 2018: 17 · 2017: 33 · 2016: 15 · 2015: 18 · 2014: 15 · 2013: 3
FWCI
1.69
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Orphanet Journal of Rare Diseases (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion, other-oa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • UCL Discovery (University College London) (submittedVersion)
Funders
Swedish Orphan Biovitrum
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Amino Acid Enzymes and Metabolism
  • Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
Keywords
nitisinone, dietary therapy, inborn errors of metabolism, management recommendations, hyperphenylalaninemia
MeSH terms
Cyclohexanones, Female, Humans, Infant, Newborn, Nitrobenzoates, Pregnancy, Psychometrics, Bone Density, Neonatal Screening, Liver Transplantation, Tyrosinemias

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Recommendations for the management of tyrosinaemia type 1. https://app.cochat.ai/papers/10.1186/1750-1172-8-8
The paper
de Laet, C., Dionisi-Vici, C., Leonard, J. V., McKiernan, P., Mitchell, G., Monti, L., de Baulny, H. O., Pintos-Morell, G., & Spiekerkötter, U. (2013). Recommendations for the management of tyrosinaemia type 1. Orphanet Journal of Rare Diseases. https://doi.org/10.1186/1750-1172-8-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.